06.05.2013 - French drug major Sanofi has licenced two ophthalmology antibody drug families to Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals, Inc. acquired exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi. The antibodies target the PDGF receptors and ligands as well as the ANG2 (angiopoietin2) receptor and ligand and will be used both in ophthalmology. The programmes are currently in preclinical development stage.
With respect to PDGF antibodies, Regeneron will pay Sanofi US$10m upfront, up to US$40m in development milestone payments, and royalties on sales. With respect to ANG2 antibodies in ophthalmology, Regeneron will pay Sanofi US$10m upfront, a potential US$5m development milestone payment, and royalties on sales. Antibodies to ANG2 outside of ophthalmology will continue to be developed by Regeneron and Sanofi under their antibody collaboration agreement, including REGN910 (SAR 307746), an antibody to ANG2 that is currently in Phase 1 development in patients with advanced malignancies.
23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.
15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.
11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.
04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.
The First Multi-Angle Light Scattering Detector for UHPLC!
The µDAWN™ Multi-Angle static Light Scattering (MALS) detector performs absolute characterization of macromolecules eluting from UHPLC, determining molar mass and size independently of retention time and molecular reference standards. more